Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) is now available in the US for the treatment of rheumatoid arthritis (RA), in combination with methotrexate, in adult patients with moderately to severely active RA who have had an inadequate response to 1 or more tumor necrosis factor antagonist therapies.
The biosimilar is also available for use in adults with granulomatosis with polyangiitis and microscopic polyangiitis, in combination with glucocorticoids.
“We are proud to make Truxima available to patients and providers as a treatment option for these indications, especially as this is the only rituximab biosimilar indicated for rheumatoid arthritis,” said Brendan O’Grady, Executive Vice President, North America Commercial, Teva.
These indications are in addition to the approved oncology indications (ie, non-Hodgkin lymphoma, chronic lymphocytic leukemia) for Truxima, which were announced in 2019.
According to Teva, the list price for Truxima will be 10% lower than the reference product ($845.55 per 100mg vial and $4,227.75 per 500mg vial).
For more information visit truximahcp.com.
